Cullinan Therapeutics (CGEM) Cash from Investing Activities (2020 - 2023)
Historic Cash from Investing Activities for Cullinan Therapeutics (CGEM) over the last 4 years, with Q4 2023 value amounting to $51.5 million.
- Cullinan Therapeutics' Cash from Investing Activities rose 27990.21% to $51.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $35.8 million, marking a year-over-year decrease of 8561.86%. This contributed to the annual value of -$136.3 million for FY2024, which is 48070.16% down from last year.
- Per Cullinan Therapeutics' latest filing, its Cash from Investing Activities stood at $51.5 million for Q4 2023, which was up 27990.21% from -$43.0 million recorded in Q3 2023.
- In the past 5 years, Cullinan Therapeutics' Cash from Investing Activities registered a high of $300.9 million during Q2 2022, and its lowest value of -$154.6 million during Q2 2021.
- Over the past 4 years, Cullinan Therapeutics' median Cash from Investing Activities value was -$8.9 million (recorded in 2020), while the average stood at -$3.4 million.
- In the last 5 years, Cullinan Therapeutics' Cash from Investing Activities plummeted by 139140.42% in 2021 and then soared by 29460.78% in 2022.
- Cullinan Therapeutics' Cash from Investing Activities (Quarter) stood at $11.4 million in 2020, then plummeted by 238.65% to -$15.9 million in 2021, then tumbled by 80.37% to -$28.6 million in 2022, then surged by 279.9% to $51.5 million in 2023.
- Its Cash from Investing Activities stands at $51.5 million for Q4 2023, versus -$43.0 million for Q3 2023 and $12.1 million for Q2 2023.